Development of innovative antimicrobials against pathogens resistant to antimicrobials

Description

Details Status Upcoming Reference HORIZON-HLTH-2027-01-DISEASE-08 Publication date 12 October 2026 in Funding and Tenders Portal Opening date 29 October 2026 Deadline model Single-stage Deadline date 17 February 2027, 17:00 (CET) Funding programme Horizon Europe – the Framework Programme for Research and Innovation (2021/2027) Programme Sector Health Programme Horizon Europe Horizon Europe Cluster 1: Health Tags EU financing Medical research Public health Description The rapid rise of AMR presents a formidable threat to public health, challenging our ability to treat infections that were once easily managed with standard antimicrobials. As pathogens continually adapt and develop resistance to existing drugs, the efficacy of these treatments diminishes, leading to more severe and prolonged illnesses, increased healthcare costs and productivity losses, and higher mortality rates. This escalating crisis underscores an urgent need for viable therapeutic alternatives required to reduce the burden of diseases caused by antibiotic resistance. Innovative solutions are crucial to maintaining effective disease management and safeguarding public health. Proposals should pursue the development of innovative and effective antibacterial and antifungal agents, including antibody-based therapies, which meet at least one of the four World Health Organization (WHO) innovation criteria, namely: i) new chemical class, ii) new target, iii) new mode of action and iv) no evidence of cross-resistance. Read more and apply on the Funding and Tenders Portal .

Sectors

Source

Source: hadea.ec.europa.eu